CTOs on the Move

Professional Gem Sciences Inc

www.progem.com

 
Professional Gem Sciences Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.progem.com
  • 5 S Wabash Ave Ste 1905
    Chicago, IL USA 60603
  • Phone: 312.920.1541

Executives

Name Title Contact Details

Similar Companies

TotalAncillary

Comprehensive Solution for Revenue Generating Medical Ancillary Services

Particle Dynamics

Particle Dynamics is a company that provides innovative technologies, quality ingredients, and custom processing capabilities that deliver solutions for the pharmaceutical, consumer health, OTC, and nutraceutical markets.

Melior Discovery

Melior Discovery Inc (Exton, PA, USA) has pioneered a unique high throughput in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. theraTRACE® is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates. Melior has also leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.

Purdue Pharma

Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.